Xtandi Plus ADT Bolsters Survival in High-risk Patients, Phase 3 Trial Finds

Xtandi Plus ADT Bolsters Survival in High-risk Patients, Phase 3 Trial Finds
Adding Xtandi (enzalutamide) to standard androgen deprivation therapy (ADT) significantly prolonged life by nearly a year for men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC), final data from a Phase 3 clinical trial show. The results, “Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer,” were published in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology (ASCO) annual meeting — held virtually due to the COVID-19 pandemic. “Overall survival is a critical endpoint in evaluating a prostate cancer medicine,” Cora N. Sternberg, MD, the study’s first author and clinical director of the Englander Institute for Precision Medicine at Weill Cornell Medicine, in New York, said in a press release. “These results add to the body of evidence supporting Xtandi’s potential to reduce the r
Subscribe or to access all post and page content.